Figure 3.
Overall reduction in the annual number of cCMV infections at equilibrium by proportion of individuals effectively vaccinated by age at vaccination, assuming age-specific duration of infectiousness, 20 year duration of latency, and a vaccine with 5-year duration of protection, United States and Brazil.